Navigation Links
NxStage Reports First Quarter 2013 Financial Results
Date:5/2/2013

s a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.

In addition, the statements in this
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
2. NxStage Names Robert G. Funari Chairman Of The Board
3. NxStage Completes Move to Direct Sales In UK
4. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
5. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
6. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
7. NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
8. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
9. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
10. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
... SiteJabber.com , a leading consumer protection service which helps people avoid fraudulent websites and find good sites, and LegitScript.com ... websites and avoid fraudulent ones. , ... ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 2SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 3
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... The Lupus Foundation of,America (LFA) is ... in grant funding,for basic, clinical, or translational ... fatal autoimmune disease. The purposes of the,studies ... novel,approaches; and develop experimental prototypes. Grants will ...
... Council (ACC) today sent a letter to FDA ... review of the safety of bisphenol A,in food ... study regarding bisphenol A is well,documented and well ... the safety and use of polycarbonate plastic and ...
... Mass., April 17 Inverness Medical,Innovations, Inc. (Amex: ... point-of-care,diagnostic products, today announced that it will release ... 2008. The Company will also host a,conference call ... date to,discuss these results and other corporate matters. ...
... They,re more disruptive than long hours, night shifts or job ... Common job-related problems such as conflicts with bosses or co-workers ... insecurity to cause poor sleep. , That,s the conclusion of ... from two surveys of about 2,300 U.S. adults who were ...
... Pennsylvania School of Medicine are developing a novel approach ... as amyotrophic lateral sclerosis (ALS), or Lou Gehrig,s disease, ... mutations have been found in a disease protein called ... of frontotemporal dementia (FTD). , We,ve created a ...
... KIRKLAND, Wash., April 17 For health reasons, Americans,in ... than they think,according to Denise Gott, Vice Chairperson of ... long term care insurance agencies.,"The sudden need for long ... "and they,re vulnerable on two fronts, not just one, ...
Cached Medicine News:Health News:Lupus Foundation of America Seeks Funding Proposals for Research Studies on Childhood Lupus, Nervous System Involvement, and More 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:Work Conflicts Can Do a Job on Your Sleep 2Health News:Penn researchers find potential in yeast for selecting Lou Gehrig's disease drugs 2Health News:Today's Working Adults Face Long Term Care 'Double Whammy,' Says Denise Gott, Spokesperson for LTC Financial Partners, LLC 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: